FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2345491145> ?p ?o ?g. }

• W2345491145 endingPage "4542" @default.
• W2345491145 startingPage "4542" @default.
• W2345491145 abstract "Abstract Background: In pts with newly diagnosed CML-CP, NIL 300 mg twice daily (BID) is generally well tolerated and results in high rates of molecular response and low rates of disease progression. The kinetics of molecular response achieved with NIL, as assessed by local laboratories, and the potential for NIL dose optimization are being investigated in Evaluating Nilotinib Efficacy and Safety in Clinical Trials—Extending Molecular Reponses (ENESTxtnd). Here, we present results from a preplanned interim analysis of ENESTxtnd based on the first 50% of pts who completed 12 mo of treatment or discontinued early. Methods: Adults from 18 countries (Algeria, Argentina, Australia, Brazil, Canada, Egypt, India, Israel, Lebanon, Malaysia, Mexico, Oman, Russia, Saudi Arabia, South Africa, Taiwan, Thailand, and Tunisia) within 6 mo of diagnosis with Philadelphia chromosome–positive (Ph+) or Ph-negative CML-CP were enrolled. Initial treatment for all pts was NIL 300 mg BID. Molecular responses were assessed at local laboratories. The primary endpoint was rate of major molecular response (MMR; BCR-ABL ≤ 0.1% on the International Scale [IS]) by 12 mo. NIL dose escalation to 400 mg BID was recommended for pts with BCR-ABLIS > 10% at 3 mo or later, lack of MMR at 12 mo, loss of MMR, or treatment failure. Dose reduction to NIL 450 mg once daily was recommended for grade 2-4 nonhematologic adverse events (AEs) and grade 3/4 hematologic AEs other than anemia. In pts with dose reduction due to AEs, dose reescalation was recommended (successful reescalation: ≥ 4 wk of treatment with NIL 300 mg BID with no dose adjustments for any AE). Results: Among 211 pts included in this analysis, median age was 49 y (range, 18-86 y) and median time from diagnosis to enrollment was 30 d (range, 0-170 d); 110 pts (52.1%) were male. Previous CML therapies included hydroxyurea (n = 153), imatinib (≤ 2 wk; n = 9), anagrelide (n = 4), interferon (n = 1), and other therapies (n = 3). By the data cutoff (March 5, 2013), 38 pts (18.0%) discontinued treatment (due to AEs [n = 19], loss to follow-up [n = 4], protocol deviation [n = 2], administrative problems [n = 2], withdrawal of consent [n = 1], disease progression [n = 1], death [n = 1; raised intracranial pressure; pt had a cerebrovascular accident before study entry], or other reasons [n = 8]). Median time on study treatment was 13.8 mo (range, 0-22 mo). Overall, 63 pts (29.9%) had a dose reduction, and 47 attempted to reescalate to 300 mg BID; among these, 37 (78.7%) successfully reescalated. Twenty-eight pts (13.3%) dose-escalated to NIL 400 mg BID due to lack of efficacy, including 10 of 15 pts with BCR-ABLIS > 10% at 3 mo. After dose escalation, 6 pts had dose interruptions due to AEs. Of pts who dose-escalated due to suboptimal response or treatment failure, 4 later discontinued due to suboptimal response (BCR-ABLIS > 1% at 6 mo [n = 1]; no MMR at 12 mo [n = 1]) or treatment failure (Ph+ > 35% at 12 mo [n = 2]). Among all pts, median actual dose intensity was 600 mg/d (range, 165-759 mg/d). By 12 mo, 152 pts achieved MMR in IS-standardized assessments and 1 additional pt achieved MMR in a non-IS assessment, for a total MMR rate by 12 mo of 72.5% (99.52% CI, 63.1%-80.7%). Among pts with a dose reduction, 42 of 63 (66.7%) achieved MMR by 12 mo; among those who attempted to reescalate to NIL 300 mg BID, 30 of 37 pts (81.1%) with successful reescalation and 4 of 10 pts (40.0%) without successful reescalation achieved MMR by 12 mo. Among pts with dose escalation to NIL 400 mg BID due to lack of efficacy, 6 of 28 (21.4%) achieved MMR by 12 mo. Median BCR-ABLIS levels decreased over time (Figure), with a median value of 0.03% (range, 0.00%-177.18%) at 12 mo. Most pts (n = 120; 56.9%) achieved complete cytogenetic response by 6 mo. Drug-related nonhematologic AEs of any grade reported in ≥ 10% of pts were rash (17.5%), headache (11.4%), nausea (10.9%), and pruritus (10.4%). New or worsening grade 3/4 laboratory abnormalities reported in ≥ 10% of pts were elevated blood lipase (13.3%), thrombocytopenia (13.3%), and neutropenia (12.8%). One pt died > 28 d after the last dose of study treatment due to acute myeloid leukemia. Conclusion: Dose-optimized NIL was well tolerated and resulted in rapid achievement of MMR in most pts. Among pts with lack of efficacy on NIL 300 mg BID, some achieved MMR after dose escalation to NIL 400 mg BID. Most pts with temporary NIL dose reductions due to AEs who attempted to dose-reescalate were able to successfully resume treatment with NIL 300 mg BID. Figure 1 Figure 1. Disclosures Hughes: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Ariad: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Shortt:Novartis: Attendance at CML expert forum, Travel sponsorship (conference attendance). Other, Honoraria; BMS: Honoraria, Travel sponsorship (conference attendance)., Travel sponsorship (conference attendance). Other. Quach:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Pavlovsky:Novartis: Speakers Bureau; BMS: Speakers Bureau. Louw:Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Meillon:Bayer: Honoraria, Speakers Bureau; Pfizer/BMS: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Amgen: Honoraria, Speakers Bureau. Shih:Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding. Turkina:Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria. Hwang:Novartis: Employment. Nidamarthy:Novartis Healthcare Pvt. Ltd. India: Employment. Dalal:Novartis: Employment. Lipton:Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Teva: Consultancy, Research Funding." @default.
• W2345491145 created "2016-06-24" @default.
• W2345491145 creator A5002629992 @default.
• W2345491145 creator A5002779673 @default.
• W2345491145 creator A5003294629 @default.
• W2345491145 creator A5003727895 @default.
• W2345491145 creator A5008888432 @default.
• W2345491145 creator A5014346242 @default.
• W2345491145 creator A5033717095 @default.
• W2345491145 creator A5043706544 @default.
• W2345491145 creator A5048644414 @default.
• W2345491145 creator A5049971021 @default.
• W2345491145 creator A5057674362 @default.
• W2345491145 creator A5063094149 @default.
• W2345491145 creator A5065221908 @default.
• W2345491145 creator A5065901710 @default.
• W2345491145 creator A5067064349 @default.
• W2345491145 creator A5091396091 @default.
• W2345491145 date "2014-12-06" @default.
• W2345491145 modified "2023-09-30" @default.
• W2345491145 title "Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis" @default.
• W2345491145 doi "https://doi.org/10.1182/blood.v124.21.4542.4542" @default.
• W2345491145 hasPublicationYear "2014" @default.
• W2345491145 type Work @default.
• W2345491145 sameAs 2345491145 @default.
• W2345491145 citedByCount "1" @default.
• W2345491145 countsByYear W23454911452017 @default.
• W2345491145 crossrefType "journal-article" @default.
• W2345491145 hasAuthorship W2345491145A5002629992 @default.
• W2345491145 hasAuthorship W2345491145A5002779673 @default.
• W2345491145 hasAuthorship W2345491145A5003294629 @default.
• W2345491145 hasAuthorship W2345491145A5003727895 @default.
• W2345491145 hasAuthorship W2345491145A5008888432 @default.
• W2345491145 hasAuthorship W2345491145A5014346242 @default.
• W2345491145 hasAuthorship W2345491145A5033717095 @default.
• W2345491145 hasAuthorship W2345491145A5043706544 @default.
• W2345491145 hasAuthorship W2345491145A5048644414 @default.
• W2345491145 hasAuthorship W2345491145A5049971021 @default.
• W2345491145 hasAuthorship W2345491145A5057674362 @default.
• W2345491145 hasAuthorship W2345491145A5063094149 @default.
• W2345491145 hasAuthorship W2345491145A5065221908 @default.
• W2345491145 hasAuthorship W2345491145A5065901710 @default.
• W2345491145 hasAuthorship W2345491145A5067064349 @default.
• W2345491145 hasAuthorship W2345491145A5091396091 @default.
• W2345491145 hasConcept C126322002 @default.
• W2345491145 hasConcept C141071460 @default.
• W2345491145 hasConcept C143998085 @default.
• W2345491145 hasConcept C2777413986 @default.
• W2345491145 hasConcept C2777583451 @default.
• W2345491145 hasConcept C2778729363 @default.
• W2345491145 hasConcept C535046627 @default.
• W2345491145 hasConcept C61943457 @default.
• W2345491145 hasConcept C71924100 @default.
• W2345491145 hasConceptScore W2345491145C126322002 @default.
• W2345491145 hasConceptScore W2345491145C141071460 @default.
• W2345491145 hasConceptScore W2345491145C143998085 @default.
• W2345491145 hasConceptScore W2345491145C2777413986 @default.
• W2345491145 hasConceptScore W2345491145C2777583451 @default.
• W2345491145 hasConceptScore W2345491145C2778729363 @default.
• W2345491145 hasConceptScore W2345491145C535046627 @default.
• W2345491145 hasConceptScore W2345491145C61943457 @default.
• W2345491145 hasConceptScore W2345491145C71924100 @default.
• W2345491145 hasIssue "21" @default.
• W2345491145 hasLocation W23454911451 @default.
• W2345491145 hasOpenAccess W2345491145 @default.
• W2345491145 hasPrimaryLocation W23454911451 @default.
• W2345491145 hasRelatedWork W1974135663 @default.
• W2345491145 hasRelatedWork W2002120878 @default.
• W2345491145 hasRelatedWork W2003938723 @default.
• W2345491145 hasRelatedWork W2047967234 @default.
• W2345491145 hasRelatedWork W2072665415 @default.
• W2345491145 hasRelatedWork W2118496982 @default.
• W2345491145 hasRelatedWork W2439875401 @default.
• W2345491145 hasRelatedWork W2935865435 @default.
• W2345491145 hasRelatedWork W4238867864 @default.
• W2345491145 hasRelatedWork W2525756941 @default.
• W2345491145 hasVolume "124" @default.
• W2345491145 isParatext "false" @default.
• W2345491145 isRetracted "false" @default.
• W2345491145 magId "2345491145" @default.
• W2345491145 workType "article" @default.